Neuropsychopharmacology
May 12, 2023
Naim Zaki, Li Chen, Rosanne Lane et al.
122 citations
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability. Adults with TRD who participated in ≥1 of 6 phase 3...
Pharmaceuticals
May 12, 2023
Philip Borsellino, Reese I. Krider, Deanna Chea et al.
Ketamine is a promising alternative to traditional pharmacotherapies for major depressive disorder, treatment-resistant depression, and other psychiatric conditions that heavily contribute to the global disease burden. In contrast to the current standard of care medications for these disorders, ketamine offers rapid onset, enduring clinical efficacy, and unique therapeutic potential for use in...
Medical Sciences
May 11, 2023
Akvilė Gečaitė, Algirdas Musneckis
Akvilė Gečaitė1, Algirdas Musneckis2 1Lithuanian University of Health Sciences, Faculty of Medicine, Kaunas, Lithuania 2The Hospital of Lithuanian University of Health Science, Kaunas, Lithuania Abstract Background. In the scientific literature, meditation practices are usually divided into two main techniques: mindfulness (open monitoring) and concentrative (transcendental). They are aiming to...
Children
May 11, 2023
Jessica Monsillion, Rafika Zebdi, Lucia Romo-Desprez
Mindfulness-based interventions (MBIs) are growing in popularity, with research concerning their efficacy with youth populations. Following a preliminary analysis of the existing literature, and given the positive effects of such programs, we felt it relevant to assess whether research has considered the implications for MBIs on children and adolescents, with regard to depression, anxiety, and...
Neurology Bulletin
May 10, 2023
Мikhail L. Zobin
Pharmacotherapy of depression based on a monoaminergic model in many cases is not enough effective. In this regard the ketamine treatment results of pharmacoresistant depression by subanaesthetic doses, including the patients with double diagnosis, are of interest. Method: in an open label naturalistic non-randomized trial, 12 patients with non-psychotic treatment-resistant depression (10 of...
Translational Psychiatry
May 9, 2023
Jared M. Kopelman, T. Keller, Benjamin Panny et al.
57 citations
Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing neuroplasticity. In human patients, we quantified gray matter microstructural changes on a rapid (24-h) timescale within key regions where neuroplasticity enhancements post-ketamine have been implicated in animal models. In this study, 98 unipolar depressed adults who failed at least one antidepressant medication...
Health and Quality of Life Outcomes
May 8, 2023
Carol Jamieson, Vanina Popova, Ella Daly et al.
18 citations
BACKGROUND: Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning. Esketamine effectively enhances the daily functioning in these patients while also improving their depressive symptoms. This study assessed HRQoL and health status of patients with TRD, who...
Journal of Affective Disorders
May 7, 2023
Wei Zheng, Yanling Zhou, Chengyu Wang et al.
OBJECTIVES This study aims to investigate the differences in safety and antidepressant effects of multi-infusion ketamine treatment between elderly and young adults with depression. METHODS The safety, antidepressant, and anti-suicidal effects of multi-infusion ketamine were compared between 19 elderly (≥50 years) and 116 younger (<50 years) adults with depression; all were treated with six...
European Neuropsychopharmacology
May 4, 2023
Stefania Chiappini, Giacomo D’andrea, Sergio De Filippis et al.
48 citations
Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety. It is also indicated for the acute short-term treatment of psychiatric emergency due to major depressive disorder (MDD) and for depressive symptoms in adults with MDD with acute suicidal...
The Brown University Psychopharmacology Update
May 3, 2023
symptoms of depression and anxiety and evaluated socio-occupational functioning. Twenty-two participants were randomized to treatment. The infusions were well-tolerated, with no serious adverse events. Most of the findings were suggestive but not statistically significant. Post-infusion scores on the primary outcome decreased more in the ketamine group than in the midazolam group. The greatest...